Skip to main content

Table 6 Univariable analysis for the association of baseline factors with BCR-free survival

From: PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

  No. of patients Hazard ratio 95% CI p value*
Clinical data
 Age 186 1.056 1.018–1.096 0.004
 iPSA 184 1.021 1.007–1.035 0.003
Pathological data
 Gleason score in surgical specimen, no., n = 186
  6–7 133 Reference   
  8–10 53 5.097 3.013–8.625 < 0.001
Pathological stage, no., n = 186
 pT status
  2 92 Reference   
  ≥ 3 94 2.935 1.665–5.173 < 0.001
 pN status
  0 154 Reference   
  1 32 3.378 1.901–6.000 < 0.001
 Surgical margin, no., n = 180
  Negative 152 Reference   
  Positive 28 3.421 1.890–6.193 < 0.001
Imaging parameters
miTNM classification, no., n = 186
 miT status
  2 125 Reference   
  ≥ 3a 61 2.811 1.673–4.722 < 0.001
 miN status
  No LN metastasis 168 Reference   
  With LN metastasis 18 2.691 1.311–5.527 0.007
  SUVmean of prostatic lesions 183 1.019 1.002–1.036 0.028
SUVmean of prostatic lesions, no. n = 183
 < median 91 Reference   
 ≥ median 92 1.752 1.030–2.981 0.039
 SUVmax of prostatic lesions 183 1.015 1.004–1.026 0.008
SUVmax of prostatic lesions, no. n = 183
 < median 91 Reference   
 ≥ median 92 1.744 1.025–2.968 0.040
 TV of prostatic lesions 183 0.948 0.909–0.988 0.011
TV of prostatic lesions, no., n = 183
 < median 91 Reference   
 ≥ median 92 0.987 0.587–1.661 0.962
 TL of prostatic lesions 183 1.003 1.000–1.006 0.072
TL of prostatic lesions, no., n = 183
 < median 91 Reference   
 ≥ median 92 0.957 0.568–1.612 0.869
  1. BCR biochemical recurrence, CI confidence interval, iPSA initial PSA, IQR interquartile range, LN lymph node, PET positron emission tomography, PSA prostate-specific antigen, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TL total lesion, TV tumor volume
  2. *Significant associations are given in bold